Condition (MeSH)
Neurocysticercosis
ClinicalTrials.gov lists 20 trials for Neurocysticercosis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
20 of the 20 trials are tagged with Neurocysticercosis itself; the rest are tagged with a narrower condition beneath it.
When did Neurocysticercosis trials start? (14)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2021 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2016 | 2 |
| 2015 | 1 |
| 2014 | 3 |
| 2011 | 1 |
Showing 10 of 14 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 20 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Neurocysticercosis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 2/3 | 3 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 2 |
| Observational | 6 |
How many Neurocysticercosis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 1 |
| Completed | 11 |
| Terminated | 3 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Neurocysticercosis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 4 |
| National Institute of Mental Health (NIMH) | 2 |
| Cephas Health Research Initiative Inc, Ibadan, Nigeria | 1 |
Which drugs are being tested for Neurocysticercosis? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Albendazole | 4 |
| Oxfendazole | 2 |
| Omeprazole 20 mg | 1 |
| Praziquantel | 1 |
| Niclosamide | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Albendazole and praziquantel | 2 |
| Dexamethasone/Dexamethasone acetate | 2 |
| 28 days of albendazole 15 mg/kg/day | 1 |
| Oxfendazole three doses | 1 |
| Oxfendazole single dose | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Neurocysticercosis trials report? (1)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Prolonged hospitalization | 4 | 1 |
Which publications cover Neurocysticercosis? (42)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Immunologic Profiling of CSF in Subarachnoid Neurocysticercosis Reveals Specific Interleukin-10-Producing Cell Populations During Treatment. | Neurology(R) neuroimmunology & neuroinflammation | 2024 | Yes |
| Knowledge and misconceptions about epilepsy among people with epilepsy and their caregivers attending mental health clinics: A qualitative study in Taenia solium endemic pig-keeping communities in Tanzania. | Epilepsia open | 2023 | Yes |
| Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study. | Infection | 2023 | Yes |
| Triplex ELISA for Assessing Durability of Taenia solium Seropositivity after Neurocysticercosis Cure. | Emerging infectious diseases | 2023 | Yes |
| A recombinant monoclonal-based Taenia antigen assay that reflects disease activity in extra-parenchymal neurocysticercosis. | PLoS neglected tropical diseases | 2022 | Yes |
Showing 5 of 42 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.